Zoetis Inc. (NYSE:ZTS) Shares Sold by Parthenon LLC

Parthenon LLC trimmed its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.0% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 10,100 shares of the company’s stock after selling 107 shares during the quarter. Parthenon LLC’s holdings in Zoetis were worth $1,993,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently added to or reduced their stakes in the company. River Street Advisors LLC lifted its stake in shares of Zoetis by 3.4% during the fourth quarter. River Street Advisors LLC now owns 1,757 shares of the company’s stock worth $347,000 after purchasing an additional 58 shares in the last quarter. Perigon Wealth Management LLC lifted its stake in shares of Zoetis by 0.3% in the fourth quarter. Perigon Wealth Management LLC now owns 23,581 shares of the company’s stock worth $4,654,000 after acquiring an additional 59 shares in the last quarter. Revolve Wealth Partners LLC lifted its stake in shares of Zoetis by 5.0% in the fourth quarter. Revolve Wealth Partners LLC now owns 1,281 shares of the company’s stock worth $253,000 after acquiring an additional 61 shares in the last quarter. Ellevest Inc. lifted its stake in shares of Zoetis by 2.4% in the third quarter. Ellevest Inc. now owns 2,790 shares of the company’s stock worth $485,000 after acquiring an additional 66 shares in the last quarter. Finally, Atria Wealth Solutions Inc. lifted its stake in shares of Zoetis by 0.4% in the third quarter. Atria Wealth Solutions Inc. now owns 15,975 shares of the company’s stock worth $2,779,000 after acquiring an additional 70 shares in the last quarter. 92.80% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, EVP Roxanne Lagano sold 363 shares of the stock in a transaction on Monday, February 12th. The stock was sold at an average price of $197.74, for a total transaction of $71,779.62. Following the completion of the sale, the executive vice president now owns 20,417 shares in the company, valued at approximately $4,037,257.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 2,209 shares of company stock worth $371,293. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently commented on ZTS shares. The Goldman Sachs Group boosted their price target on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research note on Wednesday, January 17th. Barclays cut their price target on Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 23rd. Piper Sandler reiterated an “overweight” rating and issued a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. StockNews.com lowered Zoetis from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 20th. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $195.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $216.13.

Zoetis Stock Down 0.3 %

Zoetis stock traded down $0.53 during midday trading on Tuesday, hitting $159.17. The stock had a trading volume of 3,647,859 shares, compared to its average volume of 3,147,432. The stock has a market cap of $72.80 billion, a P/E ratio of 31.39, a P/E/G ratio of 2.42 and a beta of 0.85. The business has a fifty day moving average price of $170.66 and a 200 day moving average price of $179.12. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $201.92. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, February 13th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.32 by ($0.08). The company had revenue of $2.21 billion for the quarter, compared to the consensus estimate of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same period last year, the company posted $1.15 earnings per share. Research analysts predict that Zoetis Inc. will post 5.79 EPS for the current year.

Zoetis Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be given a dividend of $0.432 per share. The ex-dividend date is Thursday, April 18th. This represents a $1.73 dividend on an annualized basis and a dividend yield of 1.09%. Zoetis’s dividend payout ratio (DPR) is presently 34.12%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.